Welcome to the Markowitz Lab


Since 2015, the Markowitz Lab at Moffitt Cancer Center has been studying the resistance mechanisms to checkpoint blockade in melanoma patients. We have published on the role of nitric oxide (NO) in mediating this resistance and success with ipilimumab therapy. Additionally, we are developing informatics tools that utilize new and existing datasets including transcriptomic (mRNA and miRNA), spatial (distance between known cell types on patient tissue slides), and proteomic and microbiotic to study these resistance mechanisms.

Our current projects are focused on the role of nitric oxide in mediating resistance to anti-PD-1 therapy (pembrolizumab/nivolumab) and other checkpoint blockade (CTLA4, LAG3) therapies. Our overarching translational research goals are threefold:

  1. Develop new therapeutic modalities for melanoma patients
  2. Develop biomarkers such that if patients are deemed unlikely to respond to therapy, they can attempt potentially more effective therapies on trial
  3. Balance therapy with immune related side effects by using biomarkers to personalize therapeutic decisions for patients



The Markowitz Lab is part of the H. Lee Moffitt Cancer Center & Research Institute located in beautiful Tampa, Florida. Moffitt, an NCI-designated comprehensive cancer center, takes a multidisciplinary approach to cancer focusing on cutting-edge discoveries that can be rapidly translated into improved preventative, diagnostic, and therapeutic advances. Moffitt's rapidly expanding research team, its world-renowned experts, and its great training programs make Moffitt an exciting environment to start and develop a career in research. At Moffitt's location in Tampa you can enjoy all of the benefits of city living while enjoying the warm weather surrounded by some of the most beautiful beaches in the U.S. (for more information about life in Tampa, click here). Join us on our mission to contribute to the prevention and cure of cancer!